Managing Symptom Burden and Optimizing Treatment Outcomes in Myelofibrosis

Learn more about myelofibrosis risk factors, novel therapies to slow disease progression and reduce symptoms, and strategies to maintain quality of life in this comprehensive activity presented by John Mascarenhas, MD, Professor of Medicine at Mount Sinai Icahn School of Medicine. Start the activity now!

STATEMENT OF NEED

Myelofibrosis is a rare myeloproliferative neoplasm characterized by the buildup of scar tissue in the bone marrow, leading to decreased erythropoiesis, progressive bone marrow failure, and anemia (Verstovsek et al, 2022). Though allogenic stem cell transplant is potentially curative, comorbidities preclude many patients from receiving this treatment. Therefore, therapeutic goals focus on slowing progression, managing complications, and maintaining quality of life. Currently, the discovery of the JAK-STAT pathway’s role in the pathogenesis of myelofibrosis is transforming the landscape, with novel agents that improve patients’ splenomegaly, systemic symptoms, survival, and overall quality of life (Verstovsek et al, 2022). However, correctly diagnosing and managing this disease using novel therapies and strategies remains challenging for clinicians. In this activity, John Mascarenhas, MD, Professor of Medicine at Mount Sinai Icahn School of Medicine, will update learners on myelofibrosis risk stratification, novel therapies to slow disease progression and reduce symptom burden, and strategies to maintain patient quality of life.

TARGET AUDIENCE

Hematologist/oncologists, nurse practitioners, physician assistants, oncology nurses, and other health care professionals involved in the treatment of patients with patients with myelofibrosis (MF).

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able t
Evaluate risk stratification criteria that can inform individualized MF management plans
Assess emerging efficacy and safety data on novel therapies for reducing symptom burden and prolonging survival in patients with MF
Apply strategies to optimize the safety and tolerability of novel MF therapies and optimize quality of life

John Mascarenhas, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director, Adult Leukemia program
The Tisch Cancer Institute